나이벡

138610KOSDAQ의료용품 및 기타 의약 관련제품 제조업

45.3 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Plunged 15.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Nabix operates in the fields of bio-regenerative materials, peptide pharmaceuticals, and oral health products, holding global certifications such as FDA, CE, and NMPA, and selling products worldwide. The company is focusing on expanding its global market through the commercialization of new products like PeptiCol EZgraft and obtaining European MDR certification, while also developing early diagnosis kits and treatments for periodontal diseases.

Number of Employees

93people

Average Salary

59.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

35.24Industry Average 15.180.0Point

2.3x industry avg (risky)

PBR

3.64Industry Average 1.090.0Point

3.3x industry avg (risky)

ROE

11.89Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

11.70Industry Average 6.860.5Point

1.7x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲44.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.0% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
나이벡, 골이식재-콜라겐 복합소재 브라질서 품목허가 추가 확보
나이벡의 골이식재 복합소재가 브라질에서 추가 품목허가를 획득하여 브라질 시장 진출이 확대되었다.
Positive
나이벡, 바이오 USA서 NP-201 글로벌 임상 전략 및 후속 파이프...
나이벡은 바이오 USA에서 글로벌 제약사들과의 파트너십 강화를 통해 핵심 파이프라인의 기술이전 및 공동개발을 성공적으로 추진하며 긍정적인 시장 반응을 얻었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 14,660Won52-week high 52,30052-week low 13,740

1-month return0.0Point

1m -15.31% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0